

March 13, 2019

**ContraFect**

MOLECULAR TREATMENTS  
FOR INFECTIOUS DISEASE



# ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

YONKERS, New York, March 13, 2019 (GLOBE NEWSWIRE) -- [ContraFect Corporation \(Nasdaq:CFRX\)](#), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in the 29<sup>th</sup> Annual Oppenheimer Healthcare Conference on Wednesday, March 20, 2019, at 3:55 PM ET in New York City. The focus will be on exebacase (CF-301), the Company's novel therapeutic candidate for *Staph aureus* bacteremia, including endocarditis, along with an update on the progress of its other pipeline assets.

A live webcast of the presentation will be available on the Investors & Media section of the Company's website at [www.contrafect.com](http://www.contrafect.com). The presentation will also be available as an archived webcast for a limited time.

## About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin platform and through the use of other novel agents. Lysins are a new therapeutic class of bacteriophage-derived, recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. We believe that the properties of our lysins will make them suitable for targeting antibiotic-resistant organisms, such as *Staphylococcus aureus* ("*Staph aureus*") and *Pseudomonas aeruginosa* ("*P. aeruginosa*"), which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. Our lead lysin candidate, exebacase (CF-301) is completing a Phase 2 clinical trial for the treatment of *Staph aureus* bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S.

Follow ContraFect on Twitter [@ContraFectCorp](#) and [LinkedIn](#).

### **Forward-Looking Statements:**

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, our ability to address life threatening infections using our therapeutic product candidates from our lysin platform and through the use of other novel agents, whether lysins are a new therapeutic class of bacteriophage-derived, recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether the properties of the Company’s lysins will make them suitable for targeting antibiotic-resistant organisms, such as *Staph aureus* and *P. aeruginosa*, and statements made regarding the presentation. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

### **Investor Relations Contacts:**

Michael Messinger  
ContraFect Corporation  
Tel: 914-207-2300  
Email: [mmessinger@contrafect.com](mailto:mmessinger@contrafect.com)

Lauren Stival  
Stern Investor Relations  
Tel: 212-362-1200  
Email: [lauren.stival@sternir.com](mailto:lauren.stival@sternir.com)



Source: ContraFect Corporation